abstract |
The present invention relates to novel compounds that are CNS-penetrant alpha-7 nicotinic receptor agonists of the general formula I: wherein m, n and o are integers from 1-2; X and Y are O, S or NR1 (wherein R1 is H, optionally substituted alkyl, an ester, an aldehyde, a ketone, optionally substituted carbamoyl, or an optionally substituted sulfamoyl); and Q is~ optionally substituted alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, bicycloalkyl, bicycloalkenyl, heterobicycloalkyl, heterobicycloalkenyl, aryl or heteroaryl. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant alpha-7 nicotinic receptor agonist for treating disorders of the central nervous system (CNS) and other disorders in a mammal, including a human. |